On January 14, 2026, Andrea Tan of Goldman Sachs established a price objective of $571 for Madrigal Pharmaceuticals, implying a potential upside of 15.6% from recent levels. This projection reflects confidence in the company’s late-stage clinical pipeline and its ability to deliver robust data from ongoing trials in non-alcoholic steatohepatitis (NASH). Goldman Sachs highlighted Madrigal’s cash runway through key inflection points expected over the next 12–18 months.

During the 44th Annual J.P. Morgan Healthcare Conference, CEO Bill Sibold and CMO Dr. David Soergel provided an update on Madrigal’s strategic priorities. They emphasized progress in the RESOLVE-IT Phase 3 trial for MASH, noting that enrollment has reached 75% of the target 2,000 patients. The management team also outlined plans to submit a New Drug Application by mid-2027, contingent on top-line results due in the third quarter of 2026.

Over the past year, Madrigal’s shares have oscillated between a high of $615 and a low of $265, underscoring significant volatility tied to clinical readouts and sector rotations. On the latest trading session, the stock declined 3.3%, with intraday prices ranging from $493.19 to $514.36. The company’s market capitalization stands at approximately $10.95 billion, and average daily volume over the past month has been around 430,000 shares.

Madrigal competes with larger players such as Intercept Pharmaceuticals and Gilead Sciences in the NASH market, which is projected to exceed $35 billion by 2028. Unlike competitors focusing on combination regimens, Madrigal’s investigational candidate targets both liver inflammation and fibrosis with a single mechanism of action. Analysts note that successful trial outcomes could establish Madrigal as a leader in monotherapy approaches for metabolic liver disease.